Table 2 Post-operation follow-up during the first 3 years by sociodemographic and clinical profile (N = 420)
Characteristic | Frequency of follow-up in the first 3 years | Total N = 420 | p* | |||
|---|---|---|---|---|---|---|
0 n = 94 | 1 n = 50 | 2 n = 79 | 3 n = 197 | |||
Age(years) | < 0.01 | |||||
< 65 | 58 (61.7%) | 39 (78.0%) | 66 (83.5%) | 189 (95.9%) | 352 (83.8%) | |
> 65 | 36 (38.3%) | 11 (22.0%) | 13 (16.5%) | 8 (4.1%) | 68 (16.2%) | |
Medical insurance coverage | < 0.01 | |||||
High (> 70%) | 16 (17.0%) | 10 (20.0%) | 24 (30.4%) | 77 (39.1%) | 127 (30.2%) | |
Medium (50–70%) | 50 (53.2%) | 29 (58.0%) | 35 (44.3%) | 83 (42.1%) | 197 (46.9%) | |
Low (< 50%) | 28 (29.8%) | 11 (22.0%) | 20 (25.3%) | 37 (18.8%) | 96 (22.9%) | |
Family history | 0.89 | |||||
Negative | 88 (93.5%) | 47 (94.0%) | 76 (96.2%) | 186 (94.4%) | 397 (94.5%) | |
Positive | 6 (6.4%) | 3 (6.0%) | 3 (3.8%) | 11 (5.6%) | 23 (5.5%) | |
Marital status | 0.31 | |||||
Unmarried | 9 (9.6%) | 2 (4.0%) | 3 (3.8%) | 10 (5.1%) | 24 (5.7%) | |
Married | 85 (90.4%) | 48 (96.0%) | 76 (96.2%) | 187 (94.9%) | 396 (94.3%) | |
Employment | 0.84 | |||||
Employed | 65 (69.1%) | 37 (74.0%) | 51 (64.6%) | 130 (66.0%) | 283 (67.4%) | |
Unemployed | 13 (13.8%) | 4 (8.0%) | 9 (11.4%) | 25 (12.7%) | 51 (12.1%) | |
Retired | 16 (17.0%) | 9 (18.0%) | 19 (24.1%) | 42 (21.3%) | 86 (20.5%) | |
Tumor size (cm) | 0.40 | |||||
0–1.9 | 33 (35.1%) | 18 (36.0%) | 33 (41.8%) | 87 (44.2%) | 171 (40.7%) | |
2–4.9 | 54 (57.4%) | 30 (60.0%) | 41 (51.9%) | 105 (53.3%) | 230 (54.8%) | |
> 5 | 7 (7.4%) | 2 (4.0%) | 5 (6.3%) | 5 (2.5%) | 19 (4.5%) | |
Positive axillary nodal status | 0.80 | |||||
0 | 47 (50.0%) | 26 (52.0%) | 46 (58.2%) | 112 (56.9%) | 231 (55.0%) | |
1–3 | 29 (30.9%) | 18 (36.0%) | 20 (25.3%) | 61 (31.0%) | 128 (30.5%) | |
4–9 | 12 (12.8%) | 4 (8.0%) | 7 (8.9%) | 16 (8.1%) | 39 (9.3%) | |
> 10 | 6 (6.4%) | 2 (4.0%) | 6 (7.6%) | 8 (4.1%) | 22 (5.2%) | |
TNM stage | 0.86 | |||||
Stage 0-I | 31 (33.0%) | 19 (38.0%) | 30 (38.0%) | 74 (37.6%) | 154 (36.7%) | |
Stage II | 46 (48.9%) | 23 (46.0%) | 35 (44.3%) | 98 (49.7%) | 202 (48.1%) | |
Stage III | 17 (18.1%) | 8 (16.0%) | 14 (17.7%) | 25 (12.7%) | 64 (15.2%) | |
Histological subtype | 0.65 | |||||
Tubular/Mucinous/Papillary | 1 (1.1%) | 3 (6.0%) | 2 (2.5%) | 8 (4.1%) | 14 (3.3%) | |
Ductal/Lobular/Mixed/Metaplastic | 90 (95.7%) | 46 (92.0%) | 76 (96.2%) | 186 (94.4%) | 398 (94.8%) | |
Ductal carcinoma in situ | 3 (3.2%) | 1 (2.0%) | 1 (1.3%) | 3 (1.5%) | 8 (1.9%) | |
ER status | 0.16 | |||||
Negative | 25 (26.6%) | 21 (42.0%) | 19 (24.1%) | 64 (32.5%) | 129 (30.7%) | |
Positive | 69 (73.4%) | 29 (58.0%) | 57 (72.2%) | 132 (67.0%) | 287 (68.3%) | |
Missing | 0 (0.0%) | 0 (0.0%) | 3 (3.8%) | 1 (0.5%) | 4 (1.0%) | |
PR status | 0.28 | |||||
Negative | 31 (33.0%) | 24 (48.0%) | 25 (31.6%) | 73 (37.1%) | 153 (36.4%) | |
Positive | 63 (67.0%) | 26 (52.0%) | 51 (64.6%) | 123 (62.4%) | 263 (62.6%) | |
Missing | 0 (0.0%) | 0 (0.0%) | 3 (3.8%) | 1 (0.5%) | 4 (1.0%) | |
HER2 status | 0.41 | |||||
Negative | 77 (81.9%) | 38 (76.0%) | 65 (82.3%) | 152 (77.2%) | 332 (79.0%) | |
Positive | 17 (18.1%) | 12 (24.0%) | 11 (13.9%) | 44 (22.3%) | 84 (20.0%) | |
Missing | 0 (0.0%) | 0 (0.0%) | 3 (3.8%) | 1 (0.5%) | 4 (1.0%) | |
Breast surgery | 0.24 | |||||
Lumpectomy | 38 (40.4%) | 20 (40.0%) | 35 (44.3%) | 101 (51.3%) | 194 (46.2%) | |
Mastectomy | 56 (59.6%) | 29 (58.0%) | 44 (55.7%) | 95 (48.2%) | 224 (53.3%) | |
Missing | 0 (0.0%) | 1 (2.0%) | 0 (0.0%) | 1 (0.5%) | 2 (0.5%) | |
Axillary surgery | 0.03 | |||||
Sentinel lymph node biopsy | 37 (39.4%) | 24 (48.0%) | 40 (50.6%) | 108 (54.8%) | 209 (49.8%) | |
Axillary lymph node dissection | 50 (53.2%) | 24 (48.0%) | 36 (45.6%) | 88 (44.7%) | 198 (47.1%) | |
Missing | 7 (7.4%) | 2 (4.0%) | 3 (3.8%) | 1 (0.5%) | 13 (3.1%) | |
Chemotherapy | < 0.01 | |||||
No | 47 (50.0%) | 12 (24.0%) | 12 (15.2%) | 28 (14.2%) | 99 (23.6%) | |
Yes | 47 (50.0%) | 38 (76.0%) | 67 (84.8%) | 169 (85.8%) | 321 (76.4%) | |
Radiotherapy | < 0.01 | |||||
No | 62 (66.0%) | 23 (46.0%) | 25 (31.6%) | 39 (19.8%) | 149 (35.5%) | |
Yes | 32 (34.0%) | 27 (54.0%) | 54 (68.4%) | 158 (80.2%) | 271 (64.5%) | |
Targeted therapy | 0.03 | |||||
No | 90 (95.7%) | 45 (90.0%) | 73 (92.4%) | 167 (84.8%) | 375 (89.3%) | |
Yes | 4 (4.3%) | 5 (10.0%) | 6 (7.6%) | 30 (15.2%) | 45 (10.7%) | |
Endocrine therapy | < 0.01 | |||||
No | 40 (42.6%) | 24 (48.0%) | 17 (21.5%) | 60 (30.5%) | 141 (33.6%) | |
Yes | 54 (57.4%) | 26 (52.0%) | 62 (78.5%) | 137 (69.5%) | 279 (66.4%) | |